Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series
Attaphol Pawarode(University of Michigan), Daniel R. Couriel(The University of Texas MD Anderson Cancer Center), Andrew C. Harris(Primary Children's Hospital), John E. Levine(Icahn School of Medicine at Mount Sinai), James A. Connelly(Michigan Center for Translational Pathology), Sung Won Choi(University of Michigan), Shin Mineishi(University of Alabama at Birmingham), Carrie L. Kitko(Vanderbilt University Medical Center), Pavan Reddy(Wichita State University), Gregory A. Yanik(University of Michigan), Brian Parkin(AdventHealth Orlando), Thomas Braun(University of Michigan), Yasser Khaled(Methodist University Hospital), John Magenau(University of Michigan), Steven C. Goldstein(University of Michigan), James L.M. Ferrara(Tisch Hospital)
Cited by 12
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Gut microbiome–derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease
|Nature Immunology|2016|727
Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma
|New England Journal of Medicine|2018|598
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
|Nature Medicine|2018|577